# IOV-SAR-201 (NCT07741877)

> A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

No report yet. It can be ordered.

- Drugs tested: lifileucel
- Indication: previously treated advanced soft tissue sarcoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07741877
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Iovance Biotherapeutics, Inc.
- Conditions: Sarcoma; Soft Tissue Sarcoma (STS); Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Dedifferentiated Liposarcoma (DDLPS)
- Interventions: Lifileucel
- Enrollment: 80
- Primary outcome: Objective Response Rate

## Indexed commentary on IOV-SAR-201 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=iov-sar-201-nct07741877
